Germany’s Health Minister Nina Warken announced that drugmakers will not be exempt from cost-cutting measures. The proposed legislation aims to cap rapidly growing costs in the statutory health insurance system.

Pharmaceutical Industry Impact

Warken stated that every sector must play its part in this reform. She acknowledged that many pharmaceutical companies are under pressure but emphasized that Germany remains an attractive location for the pharmaceutical industry due to reimbursement under the statutory health insurance scheme and opportunities for clinical trials and new medicine development.

Exempting the industry from the proposed legislation is out of the question, according to Warken. She also highlighted that Germany has the fastest access to innovative medicines compared to other European countries.

US drugmaker Eli Lilly and German peer Boehringer Ingelheim have announced plans to slash investments in Germany, citing government policy proposals. Pfizer CEO Albert Bourla has also expressed concerns about the impact of the proposed legislation on the company’s investments in Germany.

Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.